Nag J, Appasamy P, Malka H, Sedley S, Bar-Shavit R
    
    
    Int J Mol Sci. 2024; 25(15).
  
  
    PMID: 39125653
    
          PMC: 11311281.
    
          DOI: 10.3390/ijms25158083.
      
 
                                  
  
    Nag J, Grisaru-Granovsky S, Armon S, Rudina T, Appasamy P, Bar-Shavit R
    
    
    Biomedicines. 2024; 12(1).
  
  
    PMID: 38275417
    
          PMC: 10813316.
    
          DOI: 10.3390/biomedicines12010246.
      
 
                                  
  
    Stuardo-Parada A, Lopez-Munoz R, Villarroel-Espindola F, Figueroa C, Ehrenfeld P
    
    
    Med Oncol. 2023; 40(8):224.
  
  
    PMID: 37405520
    
    
          DOI: 10.1007/s12032-023-02090-x.
      
 
                                  
  
    Asanuma K, Nakamura T, Okamoto T, Hagi T, Kita K, Nakamura K
    
    
    BMC Cancer. 2022; 22(1):1075.
  
  
    PMID: 36258189
    
          PMC: 9580209.
    
          DOI: 10.1186/s12885-022-10106-4.
      
 
                                  
  
    Wang B, Zou D, Wang N, Wang H, Zhang T, Gao L
    
    
    Front Genet. 2022; 13:957655.
  
  
    PMID: 36105100
    
          PMC: 9465170.
    
          DOI: 10.3389/fgene.2022.957655.
      
 
                              
              
                              
                                      
  Protease-activated receptors in health and disease.
  
    Peach C, Edgington-Mitchell L, Bunnett N, Schmidt B
    
    
    Physiol Rev. 2022; 103(1):717-785.
  
  
    PMID: 35901239
    
          PMC: 9662810.
    
          DOI: 10.1152/physrev.00044.2021.
      
 
                                          
                                                          
  Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms.
  
    Ribelli G, Simonetti S, Iuliani M, Rossi E, Vincenzi B, Tonini G
    
    
    Front Oncol. 2021; 11:789885.
  
  
    PMID: 34966687
    
          PMC: 8711264.
    
          DOI: 10.3389/fonc.2021.789885.
      
 
                                          
                                                          
  GPCR Partners as Cancer Driver Genes: Association with PH-Signal Proteins in a Distinctive Signaling Network.
  
    Nag J, Malka H, Appasamy P, Sedley S, Bar-Shavit R
    
    
    Int J Mol Sci. 2021; 22(16).
  
  
    PMID: 34445691
    
          PMC: 8396503.
    
          DOI: 10.3390/ijms22168985.
      
 
                                          
                                                          
  Breast cancer: Muscarinic receptors as new targets for tumor therapy.
  
    Espanol A, Salem A, Sanchez Y, Sales M
    
    
    World J Clin Oncol. 2021; 12(6):404-428.
  
  
    PMID: 34189066
    
          PMC: 8223712.
    
          DOI: 10.5306/wjco.v12.i6.404.
      
 
                                          
                                                          
  Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma.
  
    Kothari A, Flick M
    
    
    Int J Mol Sci. 2021; 22(10).
  
  
    PMID: 34066284
    
          PMC: 8152032.
    
          DOI: 10.3390/ijms22105138.
      
 
                                          
                                                          
  Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation.
  
    Xulu K, Augustine T
    
    
    Int J Mol Sci. 2021; 22(8).
  
  
    PMID: 33923802
    
          PMC: 8074114.
    
          DOI: 10.3390/ijms22084153.
      
 
                                          
                                                          
  Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
  
    Zecchin D, Moore C, Michailidis F, Horswell S, Rana S, Howell M
    
    
    EMBO Mol Med. 2020; 12(8):e11987.
  
  
    PMID: 32672423
    
          PMC: 7411640.
    
          DOI: 10.15252/emmm.202011987.
      
 
                                          
                                                          
  Twist-mediated PAR1 induction is required for breast cancer progression and metastasis by inhibiting Hippo pathway.
  
    Wang Y, Liao R, Chen X, Ying X, Chen G, Li M
    
    
    Cell Death Dis. 2020; 11(7):520.
  
  
    PMID: 32647142
    
          PMC: 7347637.
    
          DOI: 10.1038/s41419-020-2725-4.
      
 
                                          
                                                          
  SPONTANEOUS CEREBROSPINAL FLUID LEAK AFTER INITIATION OF DOPAMINE AGONIST THERAPY IN MACROPROLACTINOMAS: TWO CASE REPORTS AND A LITERATURE REVIEW.
  
    Lim J, Talsania M, Azar M
    
    
    AACE Clin Case Rep. 2020; 6(2):e90-e93.
  
  
    PMID: 32524018
    
          PMC: 7282151.
    
          DOI: 10.4158/AACR-2019-0372.
      
 
                                          
                                                          
  The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer.
  
    Shiina Y, Nakajima T, Yamamoto T, Tanaka K, Sakairi Y, Wada H
    
    
    PLoS One. 2019; 14(12):e0222050.
  
  
    PMID: 31877562
    
          PMC: 6932866.
    
          DOI: 10.1371/journal.pone.0222050.
      
 
                                          
                                                          
  A combined marker based on plasma D-dimer and serum albumin levels in patients with nasopharyngeal carcinoma is associated with poor survival outcomes in a retrospective cohort study.
  
    He S, Wang Y, Wang C, Zhu M, Yang X, Chen D
    
    
    J Cancer. 2019; 10(16):3691-3697.
  
  
    PMID: 31333786
    
          PMC: 6636283.
    
          DOI: 10.7150/jca.32387.
      
 
                                          
                                                          
  Comment on "Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination"  2019, , 51.
  
    Pontarollo G, Melzow F, Reinhardt C
    
    
    Cancers (Basel). 2019; 11(3).
  
  
    PMID: 30884838
    
          PMC: 6468748.
    
          DOI: 10.3390/cancers11030374.
      
 
                                          
                                                          
  Transcriptional Landscape of PARs in Epithelial Malignancies.
  
    Nag J, Bar-Shavit R
    
    
    Int J Mol Sci. 2018; 19(11).
  
  
    PMID: 30400241
    
          PMC: 6275037.
    
          DOI: 10.3390/ijms19113451.
      
 
                                          
                                                          
  Mechanical Forces in Tumor Angiogenesis.
  
    Zanotelli M, Reinhart-King C
    
    
    Adv Exp Med Biol. 2018; 1092:91-112.
  
  
    PMID: 30368750
    
          PMC: 6986816.
    
          DOI: 10.1007/978-3-319-95294-9_6.
      
 
                                          
                                                          
  PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer.
  
    Tekin C, Shi K, Daalhuisen J, Ten Brink M, Bijlsma M, Spek C
    
    
    Oncotarget. 2018; 9(62):32010-32023.
  
  
    PMID: 30174793
    
          PMC: 6112838.
    
          DOI: 10.18632/oncotarget.25880.